Drug Profile

ANB 033

Alternative Names: ANB-033

Latest Information Update: 03 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AnaptysBio
Class Anti-inflammatories; Monoclonal antibodies
Mechanism of Action Interleukin-2 receptor beta subunit antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Coeliac disease; Inflammation
Preclinical Autoimmune disorders

Most Recent Events

29 Sep 2025 Phase-I clinical trials in Coeliac disease (Parenteral) (700358675)
06 Aug 2025 AnaptysBio plans a phase Ib trial for celiac disease in the fourth quarter of 2025
05 May 2025 Anaptys plans a phase Ib trial in undisclosed indication (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com